Literature DB >> 9815176

Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers.

D S Wilbur1, P M Pathare, D K Hamlin, K R Buhler, R L Vessella.   

Abstract

We are investigating the hypothesis that biotin multimers can be used with streptavidin and monoclonal antibody conjugates in cancer pretargeting protocols to provide a method of increasing the amount of radioactivity bound on cancer cells in patients. As part of that investigation, a series of biotinylated Starburst dendrimers (BSBDs) have been prepared and evaluated in vitro and in vivo. In this study, a new biotinidase-stabilized, water-solubilizing biotinylation reagent was prepared and reacted with Starburst (PAMAM) dendrimers, generations 0, 1, 2, 3, and 4. The reaction conditions employed resulted in perbiotinylation of generation 0 (four biotin moieties conjugated), generation 1 (eight biotin moieties conjugated), generation 2 (16 biotin moieties conjugated), and generation 3 (32 biotin moieties conjugated). With generation 4, incomplete biotinylation was achieved resulting in the largest portion of that BSBD having 51 biotin moieties (of 64 possible) conjugated. The ability of each BSBD to cross-link streptavidin (SAv) was examined in an in vitro assay. In that assay, an assessment was made of the quantity of [125I]SAv bound with polystyrene-bound SAv after treatment with the synthesized BSBDs. All BSBDs cross-linked the polystyrene-bound SAv with [125I]SAv; however, the amount of [125I]SAv bound varied with the different BSBDs. Roughly 1 equiv of [125I]SAv was bound when Starburst dendrimers containing three or four biotin moieties (generation 0) were used. Two equivalents were bound with BSBD generation 1, and 4 equiv were bound with BSBDs generations 2, 3, and 4. To assess the distribution of BSBDs generations 0, 1, and 2 in mice (at 4 h postinjection), a method was developed for radioiodinating them using the NHS ester of p-[125I]iodobenzoate ([125I]PIB). It was found that the radioiodinated BSBDs had low blood concentrations (i.e., 0.13-0.20% ID/g) at the 4 h time point. In fact, most tissues examined had low concentrations of biotinylated dendrimers, except kidney and liver. Kidney had the highest concentration of [125I]-labeled BSBDs, and its concentration increased with increasing size and charge of dendrimer (e.g., 8-48% ID/g). On the basis of the increased radioactivity observed in the in vitro assay and the rapid clearance from blood in mice, additional in vivo studies with perbiotinylated Starburst dendrimer, generation 2, are planned.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815176     DOI: 10.1021/bc980055e

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  13 in total

Review 1.  Biologically optimized nanosized molecules and particles: more than just size.

Authors:  Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-05-11       Impact factor: 4.774

Review 2.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

3.  Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium.

Authors:  M El-Sayed; M F Kiani; M D Naimark; A H Hikal; H Ghandehari
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

4.  Cationic PAMAM dendrimers disrupt key platelet functions.

Authors:  Clinton F Jones; Robert A Campbell; Zechariah Franks; Christopher C Gibson; Giridhar Thiagarajan; Adriana Vieira-de-Abreu; Sivaprasad Sukavaneshvar; S Fazal Mohammad; Dean Y Li; Hamidreza Ghandehari; Andrew S Weyrich; Benjamin D Brooks; David W Grainger
Journal:  Mol Pharm       Date:  2012-05-04       Impact factor: 4.939

5.  3H dendrimer nanoparticle organ/tumor distribution.

Authors:  Shraddha S Nigavekar; Lok Yun Sung; Mikel Llanes; Areej El-Jawahri; Theodore S Lawrence; Christopher W Becker; Lajos Balogh; Mohamed K Khan
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

Review 6.  Effects of nanomaterial physicochemical properties on in vivo toxicity.

Authors:  Kristin L Aillon; Yumei Xie; Nashwa El-Gendy; Cory J Berkland; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2009-04-20       Impact factor: 15.470

Review 7.  Dendrimers in medical nanotechnology.

Authors:  Tristan Barrett; Gregory Ravizzini; Peter L Choyke; Hisataka Kobayashi
Journal:  IEEE Eng Med Biol Mag       Date:  2009 Jan-Feb

Review 8.  Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals.

Authors:  Daniel Q McNerny; Pascale R Leroueil; James R Baker
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 May-Jun

9.  Low-Level Detection of Poly(amidoamine) PAMAM Dendrimers Using Immunoimaging Scanning Probe Microscopy.

Authors:  Chevelle A Cason; Thomas A Fabré; Andrew Buhrlage; Kristi L Haik; Heather A Bullen
Journal:  Int J Anal Chem       Date:  2012-02-08       Impact factor: 1.885

Review 10.  Radionuclide carriers for targeting of cancer.

Authors:  Stavroula Sofou
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.